靶向温度管理期间重复血栓弹力图测量对院外心脏骤停幸存者神经功能良好预后的预测价值
该前瞻性队列连续纳入成功复苏并接受靶向温度管理的非创伤性院外心脏骤停患者,排除目标温度36℃、无TEG数据及拒绝适当治疗者,在初始、目标、复温三阶段测TEG。125例中28天神经功能良好(CPC 1或2)者40例(32.0%)。良好预后组初始阶段R和LY30显著低于不良预后组(5.8 vs 8.1;0.1 vs 0.7,p<0.01),初始阶段R<5或LY30<7.5在良好预后组更常见(37.5% vs 12.9%,p=0.002;95.0% vs 72.9%,p=0.004)。多变量分析中初始阶段R<5且LY30<7.5的组合是唯一与良好神经预后独立相关的凝血指标(OR 4.508,95%CI 1.254-16.210)。
要点
- 初始阶段TEG的R<5且LY30<7.5组合与28天神经功能良好预后独立相关(OR 4.508,95%CI 1.254-16.210)。
- 良好预后组初始阶段R和LY30显著低于不良预后组(R 5.8 vs 8.1;LY30 0.1 vs 0.7,p<0.01)。
- 初始阶段R<5在良好预后组占37.5% vs 不良预后组12.9%(p=0.002);LY30<7.5占95.0% vs 72.9%(p=0.004)。
- 目标阶段和复温阶段的R、K、alpha、MA在两组间均无显著差异(p>0.05)。
- TEG结果数分钟内可获得,初始阶段R缩短或LY30未延长是神经功能完好存活的早期预测指标。
适用人群与场景
- 连续非创伤性院外心脏骤停、成功复苏并接受靶向温度管理的患者。
- 排除目标温度36℃、无TEG数据及拒绝适当治疗者。
诊断标准与关键阈值
- 主要结局为28天神经功能良好,定义为脑功能表现分类(CPC)1或2。
- TEG在靶向温度管理初始阶段、目标阶段和复温阶段三个时间点测量。
- 初始阶段R<5且LY30<7.5的组合与良好神经预后独立相关(OR 4.508,95%CI 1.254-16.210)。
研究设计与关键结果
- 前瞻性队列分析125例,平均年龄61岁,男性63.2%;28天神经功能良好40例(32.0%)。
- 良好预后组初始阶段R和LY30显著低于不良预后组(5.8 vs 8.1;0.1 vs 0.7,p<0.01)。
- 初始阶段R<5在良好预后组37.5% vs 不良预后组12.9%(p=0.002);LY30<7.5在良好预后组95.0% vs 不良预后组72.9%(p=0.004)。
- 目标阶段和复温阶段的R、K、alpha、MA在两组间均无显著差异(p>0.05)。
- 单变量分析显示不良预后组D-二聚体、凝血酶原时间和活化部分凝血活酶时间更高。
- 多变量分析中初始阶段R<5且LY30<7.5的组合是唯一与良好神经预后独立相关的凝血指标(OR 4.508,95%CI 1.254-16.210)。
证据类型、等级与局限
- 证据类型:前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- TEG结果数分钟内可获得,初始阶段R缩短或LY30未延长可作为成功复苏院外心脏骤停患者神经功能完好存活的早期预测指标。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Cardiac arrest can activate blood coagulation, which clinically manifests as obstruction of the microcirculation and multiple organ dysfunction. Thromboelastography (TEG) provides a rapid and comprehensive assessment of hemostatic processes, but there are limited data on the use of sequential TEG values during targeted temperature management (TTM) in out-of-hospital cardiac arrest (OHCA) survivors. The aim of this study was to investigate the prognostic value of coagulopathy assessed by repeated TEG to predict neurologically intact survival.
METHODS: A prospective cohort of consecutive non-trauma OHCA patients who were successfully resuscitated and treated with TTM. Patients with a target temperature of 36 ℃, no TEG data, and who declined appropriate treatment were excluded. TEG was measured at three time points of TTM (initial phase, target phase, and rewarming phase). The primary outcome was 28 day favorable neurologic function, defined as a Cerebral Performance Category of 1 or 2.
RESULTS: A total of 125 patients (mean age, 61 years; 63.2% male) were analyzed. A favorable neurologic outcome at 28 days was seen in 40 patients (32.0%). TEG values of R and LY30 in the initial phase were significantly lower in the favorable neurologic outcome group than in the unfavorable group (5.8 vs. 8.1 and 0.1 vs. 0.7, respectively; p < 0.01). TEG values of R < 5 or LY30 < 7.5 in the initial phase were more frequently seen in the favorable outcomes group than in the unfavorable group (37.5% vs. 12.9%, p = 0.002 and 95.0% vs. 72.9%, p = 0.004, respectively). However, no significant differences were seen between the two groups in other TEG values (R, K, alpha, and MA) in the target and rewarming phases (p > 0.05 for all). Univariate analysis showed higher D-dimer levels, prothrombin time, and activated partial thromboplastin time in the unfavorable outcome group. In the multivariable analysis, TEG values of combination of R < 5 and LY30 < 7.5 in the initial phase were the only coagulation profiles seen to be independently associated with favorable neurologic outcome (OR, 4.508, 95% CI, 1.254-16.210).
CONCLUSION: TEG results are available within minutes, and shorted R values or the absence of prolonged LY30 values in the initial phase are an early predictor of neurologically intact survival in successfully resuscitated OHCA patients.
参考来源
- Yu G, Kim YJ, Kim JS, et al. Prognostic value of repeated thromboelastography measurement for favorable neurologic outcome during targeted temperature management in out-of-hospital cardiac arrest survivors. Resuscitation. 2020. PMID: 32755664. doi:10.1016/j.resuscitation.2020.07.019
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。